Diurnal Group plc is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions.
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
Partnering and business development is integral to our strategy of building a leading pharmaceutical company. We forge creative partnerships with other innovative companies that advance our business.
This section provides key information for Investors.
Read about all the latest news from Diurnal here.
Diurnal is committed to transparency in its interactions. Diurnal commits to following relevant pharmaceutical codes and has published details of its transfers of value.
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision.
The Diurnal articles of association are available
The Diurnal admission document is available
The Diurnal circular dated 22 April 2021 is available
The Diurnal circular dated 12 October 2020 is available
The Diurnal circular dated 9 March 2020 is available
The Diurnal circular dated 28 May 2019 is available
The Diurnal circular dated 14 March 2018 is available
Analyst presentation dated 11 December 2018